Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 25 02 2020
revised: 11 04 2020
accepted: 08 05 2020
pubmed: 29 8 2020
medline: 17 2 2021
entrez: 29 8 2020
Statut: ppublish

Résumé

This study aimed to investigate the spatiotemporal changes in neuromelanin-sensitive MRI signal in the substantia nigra and their relation to clinical scores of disease severity in patients with early or progressing Parkinson's disease and patients with idiopathic rapid eye movement sleep behaviour disorder (iRBD) exempt of Parkinsonian signs compared to healthy control subjects. Longitudinal T1-weighted anatomical and neuromelanin-sensitive MRI was performed in two cohorts, including patients with iRBD, patients with early or progressing Parkinson's disease, and control subjects. Based on the aligned substantia nigra segmentations using a study-specific brain anatomical template, parametric maps of the probability of a voxel belonging to the substantia nigra were calculated for patients with various degrees of disease severity and controls. For each voxel in the substantia nigra, probability map of controls, correlations between signal-to-noise ratios on neuromelanin-sensitive MRI in patients with iRBD and Parkinson's disease and clinical scores of motor disability, cognition and mood/behaviour were calculated. Our results showed that in patients, compared to the healthy control subjects, the volume of the substantia nigra was progressively reduced for increasing disease severity. The neuromelanin signal changes appeared to start in the posterolateral motor areas of the substantia nigra and then progressed to more medial areas of this region. The ratio between the volume of the substantia nigra in patients with Parkinson's disease relative to the controls was best fitted by a mono-exponential decay. Based on this model, the pre-symptomatic phase of the disease started at 5.3 years before disease diagnosis, and 23.1% of the substantia nigra volume was lost at the time of diagnosis, which was in line with previous findings using post-mortem histology of the human substantia nigra and radiotracer studies of the human striatum. Voxel-wise patterns of correlation between neuromelanin-sensitive MRI signal-to-noise ratio and motor, cognitive and mood/behavioural clinical scores were localized in distinct regions of the substantia nigra. This localization reflected the functional organization of the nigrostriatal system observed in histological and electrophysiological studies in non-human primates (motor, cognitive and mood/behavioural domains). In conclusion, neuromelanin-sensitive MRI enabled us to assess voxel-wise modifications of substantia nigra's morphology in vivo in humans, including healthy controls, patients with iRBD and patients with Parkinson's disease, and identify their correlation with nigral function across all motor, cognitive and behavioural domains. This insight could help assess disease progression in drug trials of disease modification.

Identifiants

pubmed: 32856056
pii: 5898381
doi: 10.1093/brain/awaa216
doi:

Substances chimiques

Melanins 0
neuromelanin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2757-2770

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Auteurs

Emma Biondetti (E)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.

Rahul Gaurav (R)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.

Lydia Yahia-Cherif (L)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France.

Graziella Mangone (G)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
National Institute of Health and Medical Research - INSERM, Clinical Investigation Centre, Pitié-Salpêtrière Hospital, Paris, France.

Nadya Pyatigorskaya (N)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.
Department of Neuroradiology, Pitié-Salpêtrière Hospital, Public Assistance - Paris Hospitals (AP-HP), Paris, France.

Romain Valabrègue (R)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France.

Claire Ewenczyk (C)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.
Department of Neurology, Pitié-Salpêtrière Hospital, Public Assistance - Paris Hospitals (AP-HP), Paris, France.

Matthew Hutchison (M)

Biogen Inc., Cambridge, MA, USA.

Chantal François (C)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.

Jean-Christophe Corvol (JC)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
National Institute of Health and Medical Research - INSERM, Clinical Investigation Centre, Pitié-Salpêtrière Hospital, Paris, France.
Department of Neurology, Pitié-Salpêtrière Hospital, Public Assistance - Paris Hospitals (AP-HP), Paris, France.

Marie Vidailhet (M)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.
Department of Neurology, Pitié-Salpêtrière Hospital, Public Assistance - Paris Hospitals (AP-HP), Paris, France.

Stéphane Lehéricy (S)

Institut du Cerveau - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France.
ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France.
Department of Neuroradiology, Pitié-Salpêtrière Hospital, Public Assistance - Paris Hospitals (AP-HP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH